Patents by Inventor David M. Marquis

David M. Marquis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220048985
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 11180549
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 23, 2021
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution, Inc
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Publication number: 20200115445
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 16, 2020
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Publication number: 20170253651
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: March 17, 2017
    Publication date: September 7, 2017
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xioa-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 9631016
    Abstract: A pen-injector device comprising an anti-IL-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: April 25, 2017
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Publication number: 20160222104
    Abstract: A pen-injector device comprising an anti-IL-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 4, 2016
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 9340613
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 17, 2016
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Publication number: 20140099311
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 4, 2013
    Publication date: April 10, 2014
    Applicants: Applied Molecular Evolution, Inc., Janssen Biotech, Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 8153125
    Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: April 10, 2012
    Assignee: Applied Molecular Evolution, Inc.
    Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
  • Patent number: 6858210
    Abstract: The present invention provides domain 1 ?2GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 ?2GPI polypeptides and mimetics. Domain 1 of ?2GPI has been shown to bind to anti-cardiolipin (?2GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 ?2GPI polypeptides may be used to detect ?2GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 ?2GPI polypeptides.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 22, 2005
    Assignee: La Jolla Pharmaceutical Co.
    Inventors: David M. Marquis, Gilbert M. Iverson, Edward J. Victoria, David S. Jones, Matthew D. Linnik
  • Patent number: 5363915
    Abstract: A method for enhancing the recovery of petroleum from an oil bearing formation during injection of a non-condensible gas comprises the at least periodic injection of a foam forming composition or a preformed foam into the reservoir. The foam which is produced comprises a mixture of a non-condensible gas, water and a non-ionic surfactant. The non-ionic surfactants which can be employed in the present invention are those non-ionic surfactants which have a HLB value of about 14 to less than 20, preferably 15-18, and which provide a stable foam when the surfactant is mixed with brine and/or water and a non-condensible gas. The method is preferably employed within a light oil bearing carbonate formation.
    Type: Grant
    Filed: July 2, 1990
    Date of Patent: November 15, 1994
    Assignee: Chevron Research and Technology Company
    Inventors: David M. Marquis, Donald L. Kuehne
  • Patent number: 5076357
    Abstract: A method for enhancing the recovery of petroleum from an oil bearing formation during injection of a non-condensible gas comprises the at least periodic injection of a foam forming composition or a preformed foam into the reservoir. The foam comprises a mixture of a non-condensible gas, preferably CO.sub.2, water and an alpha-olefin sulfonate. The alpha-olefin sulfonate comprises a mixture of hydroxy-sulfonates and alkene-sulfonates wherein the ratio of alkene-sulfonates to hydroxy-sulfonates is preferably not greater than about 4. In addition, the hydroxy-sulfonates comprises 3-hydroxy and 4-hydroxy-sulfonates wherein the ratio of 3-hydroxy-sulfonates to 4-hydroxy-sulfonates is at least about 2. The method is preferably employed within a light oil bearing formation comprising sandstone.
    Type: Grant
    Filed: May 31, 1990
    Date of Patent: December 31, 1991
    Assignee: Chevron Research & Technology Company
    Inventor: David M. Marquis
  • Patent number: 4340758
    Abstract: A process for the preparation of 2,6-dialkylaniline which comprises the reaction of 1,3-dialkylbenzene with isobutene in the presence of a hydrogen fluoride catalyst to form 1,3-dialkyl-5-tertiary-butylbenzene, which is subsequently nitrated in the presence of a soluble mercuric salt catalyst to form 2-nitro-1,3-dialkyl-5-tertiary-butylbenzene, which is then catalytically hydrogenated to give 2,6-dialkyl-4-tertiary-butylaniline, followed by pyrolysis in the presence of a heterogeneous acidic catalyst.
    Type: Grant
    Filed: July 6, 1981
    Date of Patent: July 20, 1982
    Assignee: Chevron Research Company
    Inventors: Seymour J. Lapporte, David M. Marquis
  • Patent number: 4259246
    Abstract: A process for producing maleic anhydride from a C.sub.4 hydrocarbon selected from n-butane and n-butene feed which comprises: (a) feeding the C.sub.4 hydrocarbon and air to a reactor; (b) contacting the C.sub.4 hydrocarbon and air in the reactor with a catalyst comprising vanadium and phosphorus oxides at reaction conditions including a temperature between 550.degree. and 1000.degree. F. so as to obtain a reactor effluent containing maleic anhydride, unreacted butane, nitrogen, oxygen, and acrylic, acetic or maleic acid or mixtures of the foregoing acids; (c) removing maleic anhydride from the reactor effluent to obtain maleic anhydride-lean effluent; (d) removing said acids from at least a portion of the maleic anhydride-lean effluent to obtain a purified recycle stream containing less than 100 ppm of the acids; and (e) recycling the purified stream to the reactor. Preferably the acids are removed in step (d) by water and/or caustic scrubbing the maleic anhydride-lean effluent.
    Type: Grant
    Filed: October 15, 1979
    Date of Patent: March 31, 1981
    Assignee: Chevron Research Company
    Inventors: Kiran R. Bakshi, David M. Marquis, Stephen G. Paradis
  • Patent number: 4231943
    Abstract: A process for producing maleic anhydride from n-butane which comprises:(a) feeding n-butane and air to a reactor;(b) contacting the butane and air with a catalyst comprising vanadium and phosphorus oxides at reaction conditions including a temperature between 550.degree. F. and 1000.degree. F. so as to convert 15 to 28% of the butane per pass and obtain a reactor effluent containing maleic anhydride, unreacted butane, nitrogen, and oxygen;(c) removing maleic anhydride from the reactor effluent to obtain maleic anhydride-lean effluent;(d) recycling a portion of the maleic anhydride-lean effluent to the reactor;(e) removing butane from the other portion of the maleic anhydride-lean effluent; and(f) recycling the removed butane to the reactor.Preferably the temperature in, and/or space velocity through, the reactor is adjusted to obtain a weight percent selectivity to maleic anhydride of at least 90% of the butane converted.
    Type: Grant
    Filed: May 31, 1979
    Date of Patent: November 4, 1980
    Assignee: Chevron Research Company
    Inventors: Stephen G. Paradis, David M. Marquis, Kiran R. Bakshi
  • Patent number: 4187235
    Abstract: A crystalline vanadium (IV) phosphate composition having an intrinsic surface area in excess of 10 square meters per gram is prepared by the reaction of orthophosphoric acid with a vanadium (IV) oxycompound. The vanadium compound is suspended in a suitable hydroxylic organic medium, for example isobutanol, and contacted with the acid at a temperature in the range 20.degree. C. to 210.degree. C. until the conversion is completed. The catalyst is used in the oxidation of n-butane to maleic anhydride.
    Type: Grant
    Filed: September 22, 1978
    Date of Patent: February 5, 1980
    Assignee: Chevron Research Company
    Inventors: Kiyoshi Katsumoto, David M. Marquis
  • Patent number: 4132670
    Abstract: A crystalline vanadium (IV) phosphate composition having an intrinsic surface area in excess of 10 square meters per gram is prepared by the reaction of orthophosphoric acid with a vanadium (IV) oxycompound. The vanadium compound is suspended in a suitable hydroxylic organic medium, for example isobutanol, and contacted with the acid at a temperature in the range 20.degree. C. to 210.degree. C. until the conversion is completed.
    Type: Grant
    Filed: October 6, 1976
    Date of Patent: January 2, 1979
    Assignee: Chevron Research Company
    Inventors: Kiyoshi Katsumoto, David M. Marquis
  • Patent number: 4071540
    Abstract: An absorption process for separating a maleic or phthalic anhydride from a gaseous mixture containing the anhydride which comprises contacting the gaseous mixture with a liquid absorbent comprising polymethylbenzophenones, at least a portion of which benzophenones contain at least 3 methyl groups, at a temperature for the absorbent between about 20.degree. and 235.degree. C and at a pressure sufficient to effect absorption of the anhydride into the absorbent. Preferably the absorption process is used to remove maleic anhydride from a gas stream, preferably the absorbent includes dixylylketone, and preferably the absorption is carried out by countercurrent contacting in an absorber column.
    Type: Grant
    Filed: August 6, 1976
    Date of Patent: January 31, 1978
    Assignee: Chevron Research Company
    Inventor: David M. Marquis